According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:
1. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the top general drug manufacturer stock with a Zen Score of 60, which is 19 points higher than the general drug manufacturer industry average of 41. It passed 21 out of 38 due diligence checks and has strong fundamentals. Gilead Sciences has seen its stock lose -23.74% over the past year, underperforming other general drug manufacturer stocks by -35 percentage points.
Gilead Sciences has an average 1 year
price target of $80.70, an upside of 23.64% from Gilead Sciences's current stock price of $65.27.
Gilead Sciences stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Gilead Sciences, 10% have issued a Strong Buy rating, 10% have issued a Buy, 80% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the second best general drug manufacturer stock with a Zen Score of 60, which is 19 points higher than the general drug manufacturer industry average of 41. It passed 22 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -11.12% over the past year, underperforming other general drug manufacturer stocks by -22 percentage points.
Johnson & Johnson has an average 1 year
price target of $176.88, an upside of 20.47% from Johnson & Johnson's current stock price of $146.82.
Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Johnson & Johnson, 37.5% have issued a Strong Buy rating, 25% have issued a Buy, 37.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Astrazeneca (NASDAQ:AZN)
Astrazeneca (NASDAQ:AZN) is the third best general drug manufacturer stock with a Zen Score of 52, which is 11 points higher than the general drug manufacturer industry average of 41. It passed 19 out of 38 due diligence checks and has strong fundamentals. Astrazeneca has seen its stock lose -0.83% over the past year, underperforming other general drug manufacturer stocks by -12 percentage points.
Astrazeneca has an average 1 year
price target of $82.50, an upside of 9.96% from Astrazeneca's current stock price of $75.03.
Astrazeneca stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Astrazeneca, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.